# OnCo record paper-nct02257736-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct02257736-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct02257736-lancet-oncol-2021" ;
  schema:name "Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study"@en ;
  schema:description "Published report from the trial registered as NCT02257736, in The Lancet Oncology (2021), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct02257736-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(21)00402-2>, <https://pubmed.ncbi.nlm.nih.gov/34600602/>, <https://europepmc.org/article/MED/34600602>, <https://clinicaltrials.gov/study/NCT02257736> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(21)00402-2> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Saad F, Efstathiou E, Attard G, et al." ;
  onco:trials <https://onco.cc/trials/nct02257736/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .